# Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

> **NCT05399537** · PHASE3 · RECRUITING · sponsor: **Vantive Health LLC** · enrollment: 40 (estimated)

## Conditions studied

- Regional Citrate Anticoagulation (RCA)
- Continuous Renal Replacement Therapy (CRRT)
- Acute Kidney Injury (AKI)

## Interventions

- **DRUG:** Prismocitrate 18
- **DEVICE:** PrisMax System Version 3.x with calcium line accessory

## Key facts

- **NCT ID:** NCT05399537
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05399537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05399537, "Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT05399537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*